The American Heart Association published the results of a trial that shows stroke survivors are twice as likely to take anti-blood clot treatments when they are using an artificial intelligence (AI) platform, compared to those receiving more traditional treatment. The AI platform, AiCure, uses software algorithms on smartphones to confirm patient identify, the medication, and if the medication was taken. Patients receive automated reminders and dosing instructions as well. Healthcare workers receive real-time data which allows for early detection of patients who are not taking their meds as scheduled. SEE: Google's DeepMind and the NHS: A glimpse of what AI means for the future of healthcare (ZDNet) This latest trial, which lasted 12 weeks and was published in the American Heart Association's journal Stroke, shows more of AI's potential.

Artificial intelligence is increasingly being harnessed in various aspects of drug development, from discovering compounds with life-saving potential, to identifying potential patients, and more. Outsourcing-Pharma recently spoke with Rich Christie, chief medical officer of AI-focused solutions provider AiCure, about how AI can be used to analyze and predict patient behavior, develop precision medicine solutions, and improve both care and quality of life. OSP: Could you please share the'elevator presentation' description of AiCure--who you are, what you do, and what sets you apart from other companies operating in the same space? RC: AiCure is a patient-focused technology company that empowers life science and healthcare organizations with actionable insights to accelerate drug development and improve patient care. With more than a decade of experience managing complex protected health information (PHI) in regulated settings, AiCure helps organizations to optimize care at each step of the clinical continuum by delivering objective, predictive behavioral, and interventional insights, uniquely built on unbiased patient-level audio and visual data capture.

Artificial intelligence and other forms of advanced data analysis frequently are viewed as completely impartial and free of bias. However, when the people that set up the processes inadvertently introduce bias, the results can be impacted. Rich Christie, chief medical officer of AiCure, recently connected with Outsourcing-Pharma to talk about the problems that bias in AI can lead to in trials and development. OSP: Could you please share some perspective on bias around clinical trial data? Specifically, how can AI and other advanced analytical tools (largely seen as objective) be slanted toward one group and/or against another?

AiCure and OncoBay Clinical have announced a partnership to provide oncology sponsors with scalable, AI-powered insights. A subsidiary of the Moffitt Cancer Center, OncoBay will make AiCure's proprietary AI platform available for oncology trials, aiming to provide sponsors and sites with a more holistic understanding of patient health and site optimization. The oncology drug pipeline has grown by 63% since 2013, but the average success rate of oncology drugs is only 3.4%. To address this discrepancy and the unique challenges of oncology trials, particularly given the complex treatment regimens, AiCure and OncoBay aim to improve patient support and trial retention, while also providing sponsors and sites with greater visibility into patient behavior. Through AiCure's patient engagement solution, Patient Connect, oncology sites can remotely monitor patients and use real-time communication tools to guide them through treatment protocols, including which medication to take and when, as well as allow direct access to a clinician.

It's no secret that big tech companies like Amazon (AMZN), Microsoft (MSFT), and Alphabet (GOOG), the parent company of Google, are investing in digital healthcare. The market opportunity is pretty enticing when you consider that the U.S. alone spent $3.65 trillion on healthcare just last year. Google made the latest headline-grabbing move when it announced that it would buy wearables-maker Fitbit (FIT) in a deal valued at $2.1 billion. Analysts have noted that the acquisition is part of the company's overall strategy to build an ambient intelligent system where Google is omnipresent. Another motive behind the purchase – pending regulatory approvals – is that Fitbit gives Google access to a treasure trove of healthcare data that it can feed to its London-based AI lab DeepMind or its life sciences subsidiary Verily, which is already collaborating on at least one AI healthcare device for remote patient monitoring.

It's no secret that big tech companies like Amazon (AMZN), Microsoft (MSFT), and Alphabet (GOOG), the parent company of Google, are investing in digital healthcare. The market opportunity is pretty enticing when you consider that the U.S. alone spent $3.65 trillion on healthcare just last year. Google made the latest headline-grabbing move when it announced that it would buy wearables maker Fitbit (FIT) in a deal valued at $2.1 billion. Analysts have noted that the acquisition is part of the company's overall strategy to build an ambient intelligent system where Google is omnipresent. Another motive behind the purchase – pending regulatory approvals – is that Fitbit gives Google access to a treasure trove of healthcare data that it can feed to its London-based AI lab DeepMind or its life sciences subsidiary Verily, which is already collaborating on at least one AI healthcare device for remote patient monitoring.

AiCure, a nearly decade-old startup using artificial intelligence to measure medication adherence and other behavior during clinical trials or normal care, has brought in $24.5 million in Series C funding. Palisades Growth Capital led the raise, which also featured new backers Singtel Innov8, Asahi Kasei Corporation, Accelmed Growth Partners, and SpringRock Ventures. The round also included all of the company's existing institutional investors: Baird Capital, New Leaf Venture Partners, the Pritzker Group, Biomatics Capital, Tribeca Venture Partners, and Silicon Valley Bank. AiCure's interactive medical assistant, or IMA, collects visual and audio data from patients to quantify their engagement with a treatment program, allowing the tool to identify patients who are at higher risk of dropout or non-adherence. While care providers can use these capabilities to better target their therapies and cut off preventable medical costs, drug developers can also use these trends to hone in on underperforming trial sites identify enrollees who are deliberately not participating.

This research report presents a comprehensive overview of the worldwide market for Artificial Intelligence In Life Sciences discusses the driving forces, limiting factors, opportunities, and challenges of this market at length. This detailed evaluation of the driving factors, obstacles, and the prominent market trends assists the companies in understanding the issues they may face while functioning in this market over the coming years. After studying key companies, the report focuses on the startups contributing towards the growth of the market. Possible mergers and acquisitions among the startups and key organizations are identified by the report's authors in the study. Most companies in the Artificial Intelligence In Life Sciences market are currently engaged in adopting new technologies, strategies, product developments, expansions, and long-term contracts to maintain their dominance in the global market.

Artificial intelligence is currently a white-hot buzzword in healthcare. Both in everyday conversations and in large context settings like HIMSS, the term is guaranteed to generate interest. But what can it actually achieve in the world of healthcare? This question will be a topic of discussion at the upcoming MedCity INVEST conference in Chicago. IDx chairman and CEO Gary Seamans, who will be speaking at the event, commented on the popular nature of the technology.

Description We are seeking a Project Manager to join our company and intelligently impact the lives of millions of patients. We are seeking someone passionate about client success and client engagement. ABOUT AICURE At AiCure, we build and deploy advanced artificial intelligence technologies to optimize patient behavior and medication adherence. The company was founded in 2010 to revolutionize patient monitoring with the ultimate goal of keeping the patients we love alive longer and out of the hospital. Our advanced AI platform is now used in clinical research and high-risk patient populations to ensure that medication is being taken properly.